BPC-157 effectiveness often shows through reduced GI symptoms or faster recovery from minor injuries
Who responds best to CagriSema Ideal candidates: Significant obesity (BMI 30-40+) Previously plateaued on GLP-1s alone Need maximum weight loss Good GI tolerability Metabolic syndrome or diabetes Commitment to long-term use Excellent responders: Higher baseline weight (more to lose) Good adherence to protocol Combine with diet/exercise Younger patients (better metabolism) No significant medication interactions May respond less optimally: Very low starting weight (BMI 30%): Nausea (most common) Decreased appetite (intended effect) Constipation Fatigue (especially first months) Common (10-30%): Vomiting (if nausea not managed) Diarrhea (alternating with constipation) Abdominal pain/discomfort Headache Dizziness Less common ( 40 with comorbidities Insurance covers surgery Want permanent solution Don't want ongoing injections Sourcing cagrilintide and semaglutide Obtaining these peptides requires understanding current availability
In cosmetic and wellness applications, it is widely used for improving skin elasticity, reducing fine lines, and supporting hair growth
Weeks 14 (Hydration and Plumpness): You may notice slight improvements in skin hydration and a plumper feel due to better moisture retention
The designation recognizes the KCUC team, specifically doctors Jason Anast, MD, Susan Sweat, MD, and Gerald Park, MD, for their expertise with UroLIFT Therapy
